GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings
Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...
Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...
Medpage Today on MSN1d
GLP-1 Agents' Risks and Benefits Broader Than Previously ThoughtGLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...
Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinfo ...
From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.
A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.
News Medical on MSN1d
Researchers create an atlas of health associations for GLP-1 receptor agonistsInsights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback